| The emerging role of real-world data in advanced breast cancer therapy: Recommendations for collaborative decision-making
|
| Author(s): Paul Cottu 1, Scott David Ramsey 2, Oriol Solà-Morales 3, Patricia A Spears 4, Lockwood Taylor 5 |
| Affiliations(s): 1Department of Medical Oncology, Institut Curie, 26 Rue D'Ulm, 75005, Paris, France. Electronic address: paul.cottu@curie.fr.
2Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M2-B232, Seattle, WA, 98155, USA. Electronic address: sramsey@fredhutch.org.
3Health Innovation Technology Transfer Foundation, Aragó 60, E-08015, Barcelona, Spain. Electronic address: osola@fhitt.org.
48605 Carolingian Court, Raleigh, NC, 27615, USA. Electronic address: paspears88@gmail.com.
5Epidemiology, Real World Solutions at IQVIA, 4820 Emperor Boulevard, Durham, NC, 27703, USA. Electronic address: lockwood.taylor@iqvia.com. |
Publication(s): Breast. 2021 Dec 22;61:118-122. doi: 10.1016/j.breast.2021.12.015.
|
| Document Type(s): Article, |
| Countries: France, Italy, USA, |
| Click here for the abstract |
C:
Y: |
Comparative Effectiveness & Health Technology Assessment, Drug safety, Oncology, Regulatory,
2022 |
|
L:
A: |
English
Review, |
|
 |
| |
| |
| Evidence synthesis in pulmonary arterial hypertension: a systematic review and critical appraisal |
| Author(s): Max Schlueter, Amélie Beaudet, Evan Davies, Binu Gurung, Andreas Karabis |
| Affiliations(s): IQVIA, 210 Pentonville Road, London, N1 9JY; IQVIA, Herikerbergweg 314, 1101 CT, Amsterdam, Netherlands; Department of Statistical Science, University College London, London, WC1E 6BT, UK. |
Publication(s):
|
| Document Type(s): Article, |
| Countries: |
| Click here for the abstract |
C:
Y: |
Comparative Effectiveness & Health Technology Assessment, Methodology, Rare Diseases,
2020 |
|
L:
A: |
English
Literature Review, Review, |
|
|
| |
| |
| Cost-utility model for 2nd generation treatment of chronic HCV in general population: impact of EASL recommendations in 2016 and 2018 |
| Author(s): Nat?lia Pascual-Argent? (1,2); Carlos Crespo (1,3); Laura Planellas (4); M?riam Solozabal (4), N?ria Perulero (4); Jaume Puig-Junoy (1,2) |
| Affiliations(s): (1) UPF Barcelona School of Management; (2) Dept. Econom?a y Empresa ? CRES UPF; (3) Universitat de Barcelona; (4) HEOR-RWE, IQVIA Spain |
Publication(s): XXXIX Jornadas de Econom?a de la Salud. Albacete, 12 al 14 de junio de 2019
|
| Document Type(s): Poster, |
| Countries: Spain, |
| Click here for the abstract |
C:
Y: |
Comparative Effectiveness & Health Technology Assessment, Health economics, Infectious disease,
2019 |
|
L:
A: |
Spanish
Clinical setting: hospital, Cost effectiveness, |
|
|
| |
| |
| Assessing the Outcomes for Orphan Status or Accelerated Assessment EMA Approved Medicines: A Comparison of Health Technology Assessment in Denmark, Finland, Norway and Sweden |
| Author(s): Falla, Edel; Pitcher, Ashley; Acs, Annabel; Heller, Vincent; Zhang, Rongrong |
| Affiliations(s): IQVIA, Real-World Insights, London, LON, UK
IQVIA, Real-World Insights, Copenhagen, Denmark
IQVIA, Real-World Insights, Copenhagen, Denmark
IQVIA, Real-World Insights, Solna, AB, Sweden
IQVIA, Real-World Insights, Stockholm, Sweden |
Publication(s): ISPOR Europe 2019, November 5, 2019, Copenhagen, Denmark
|
| Document Type(s): Poster, |
| Countries: Denmark, Finland, Nordic, Norway, Sweden, |
| Click here for the abstract |
C:
Y: |
Comparative Effectiveness & Health Technology Assessment,
2019 |
|
L:
A: |
English
Review, |
|
|
| |
| |
| LIMITATIONS AND EXPECTED CHALLENGES OF CAR-T ECONOMIC EVALUATION. |
| Author(s): Allou A*, Carette J*, Minacori R*, Touahmia S*, Bourguignon S*, Troubat A*, Maurel F* |
| Affiliations(s): IQVIA France - RWI |
Publication(s): ISPOR 2018
|
| Document Type(s): Poster, |
| Countries: France, |
C:
Y: |
Comparative Effectiveness & Health Technology Assessment, Health economics, Hematology,
2018 |
|
L:
A: |
English
Cost effectiveness, Market impact, Review, |
|
|
| |
| |
| WHAT INTERPRETATION OF ICERS IN ORPHAN DISEASES? A FRENCH EXAMPLE. |
| Author(s): Moutier Hélène; Bourguignon Sandrine; Maurel Frédérique; Bodaghi Charles |
| Affiliations(s): RWI IQVIA France |
Publication(s): ISPOR 2018
|
| Document Type(s): Poster, |
| Countries: France, |
C:
Y: |
Comparative Effectiveness & Health Technology Assessment, Health economics, Pricing and reimbursement, Rare Diseases,
2018 |
|
L:
A: |
English
Cost effectiveness, Pricing & Reimbursement, Willingness to pay, |
|
|
| |
| |
| ASSESSMENT OF THE UNIT COSTS IN IMAGING ACTS: THE EXAMPLE OF MRI AND CT-SCAN ACTS IN France |
| Author(s): Vasilescu L., Faller M., Allou A. |
| Affiliations(s): IQVIA France - RWI |
Publication(s): ISPOR 2018
|
| Document Type(s): Poster, |
| Countries: France, |
C:
Y: |
Comparative Effectiveness & Health Technology Assessment, Methodology,
2018 |
|
L:
A: |
English
Literature Review, Public Health, Review, |
|
|
| |
| |
| A COST-EFFECTIVENESS ANALYSIS COMPARING THE ORIGINATOR RECOMBINANT HUMAN ALFA TO THEIR BIOSIMILARS FOLLITROPIN ALFA FOR THE TREATMENT OF INFERTILITY. |
| Author(s): Ravonimbola H(1), Petrica N (1), Maurel F(1), Murphy C(2), Doré C(2), Fresneau L(2), |
| Affiliations(s): (1) QuintilesIMS, Paris France (2) Merck Serono, France |
Publication(s): ISPOR 2017
|
| Document Type(s): Poster, |
| Countries: France, |
| Click here for the abstract |
C:
Y: |
Comparative Effectiveness & Health Technology Assessment,
2017 |
|
L:
A: |
English
Cost effectiveness, Literature Review, Randomised controlled trial, |
|
|
| |
| |
| HEALTH-ECONOMICS EVALUATIONS IN FRANCE, ENGLAND, CANADA AND AUTRALIA: COMPARISON OF METHODOLOGIES AND IMPACT ON DRUGS |
| Author(s): Bucher D*, Abalan M-E*, Allou A*, Dumon L*, Vialard L *, Troubat A*, Maurel F* |
| Affiliations(s): IQVIA France - RWI |
Publication(s): ISPOR 2017
|
| Document Type(s): Poster, |
| Countries: Australia, Canada, France, UK, |
C:
Y: |
Comparative Effectiveness & Health Technology Assessment,
2017 |
|
L:
A: |
English
Cost effectiveness, Literature Review, Pricing & Reimbursement, Review, |
|
|
| |
| |
| RiGOR: a prospective observational study comparing the effectiveness of treatment strategies for open-angle glaucoma. |
| Author(s): Coleman AL1,2, Lum FC1, Velentgas P3, Campion D3, Su Z3, Gliklich RE4; RiGOR Study Group. |
| Affiliations(s): 1H. Dunbar Hoskins Jr, MD Center for Quality Eye Care, Foundation of the American Academy of Ophthalmology, 655 Beach Street, San Francisco, CA 94109, USA.
2Jules Stein Eye Institute, David Geffen School of Medicine & Fielding School of Public Health, University of California, Los Angeles, CA 90095, USA.
3Outcome DEcIDE Center, Quintiles Real World & Late Phase Research, Cambridge, MA 02139, USA. |
Publication(s): Journal of Comparative Effectiveness. Jan 2016; 5(1), 65-78
|
| Document Type(s): Article, |
| Countries: |
| Click here for the abstract |
C:
Y: |
Comparative Effectiveness & Health Technology Assessment,
2016 |
|
L:
A: |
English
Observational study, Prospective study, RWLPR (Real-World Late Phase Research-quintiles, |
|
|
| |
| |
 1 of 4 
|
